INTEGRIN CD18 IS A NOVEL STROMAL STEM CELL MARKER AND FUNCTIONS TO PROMOTE OSTEOGENESIS

• Main Authors: SHI, SONGTAO, MIURA, YASUO, ZHANG, LI
• Format: Patent
• Language: English; French
• Published: 16.03.2006
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION; TECHNICAL SUBJECTS COVERED BY FORMER USPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS; TESTING; VINEGAR; WINE

The present invention is directed to a new bone marrow stromal stem cell (BMSSC) marker, CD18, for use in selecting a population of cells enriched in BMSSCs, from bone marrow cells, adipose cells, or peripheral blood. The invention is further directed to methods for selecting a population of cells enriched in BMSSCs based on the selective expression of CD18 on their surface, using techniques known in the art such as fluorescent assisted cell sorting, an immunomagnetic method, flow microfluorimetry, immunofluorescence, immunoperoxidase staining, radioimmunoassay and immunoaffinity chromatography. The invention is further directed to the BMSSCs isolated based on CD18 expression, and their use to treat various diseases. In one aspect, the BMSSCs are transformed with a vector having a normal gene for CD18, and the transformed BMSSCs are administered to treat bone degenerative diseases and diseases of bone involving abnormal expression of CD18 expression of CD18. La présente invention concerne un nouveau marqueur de cellules souches stromales de moelle osseuse (CSSMO) appelé CD18 destiné à être utilisé pour sélectionner une population de cellules enrichies en CSSMO, parmi des cellules de moelle osseuse, des adipocytes ou du sang périphérique. Cette invention concerne également des méthodes de sélection d'une population de cellules enrichies en CSSMO qui sont fondées sur l'expression sélective de CD18 à leur surface, au moyen de techniques connues dans l'art, telles que le tri de cellules assisté par fluorescence, une méthode immunomagnétique, la microfluorimétrie de flux, l'immunofluorescence, la coloration à l'immunoperoxydase, le dosage radio-immunologique et la chromatographie d'immunoaffinité. Cette invention se rapporte également aux CSSMO isolées sur la base de l'expression de CD18 ainsi qu'à leur utilisation pour traiter diverses maladies. Selon un aspect, les CSSMO sont transformées avec un vecteur ayant un gène normal pour CD18 et les CSSMO transformées sont administrées pour traiter les maladies dégénératives osseuses et les maladies des os impliquant l'expression anormale de CD18 ou l'expression de CD18.